3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
6
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Recurrence
1
Ovarian Neoplasms
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
113
Carboplatin
99
Bevacizumab
59
pembrolizumab
56
liposomal doxorubicin
56
Gemcitabine
42
olaparib
39
Topotecan
33
niraparib
29
Nivolumab
21
Cisplatin
21
Doxorubicin
17
Cyclophosphamide
17
1-dodecylpyridoxal
16
Drug Therapy
15
Docetaxel
15
avelumab
13
Fulvestrant
11
oregovomab
10
Oxaliplatin
10
rucaparib
9
fludarabine
9
Injections
9
Fluorouracil
9
veliparib
8
mirvetuximab soravtansine
8
atezolizumab
8
Cetuximab
8
fluzoparib
7
cemiplimab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ovarian Neoplasms
×
Palliative Care
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled